Wall Street Journal: “New details about the first human study of Moderna Inc.’s experimental coronavirus vaccine emerged Tuesday, which researchers said reinforced their decision to take the shot into a large, decisive clinical trial scheduled to start in late July.”
“The new results, published online by the New England Journal of Medicine, showed that the vaccine induced the desired immune response for all 45 people evaluated—a larger group than in the preliminary data Moderna released in May—and was generally safe and well-tolerated.”
“‘This is really quite good news,’ Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said in an interview Tuesday. NIAID co-developed the Moderna vaccine and led the study.”